Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral esketamine add-on for treatment-resistant major depressive disorder
2015-003957-16Phase 3Active
- Sponsor
- University Medical Center Groningen
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of esketamine in major depressive disorder (MDD) (2 arms), sponsored by University Medical Center Groningen. Primary endpoints: Change in depressive symptom severity, Response rate and 1 more. Started Aug 2016; status: active.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2015-003957-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003957-16.